Speaker Details

Markus Rarbach

Head of Business Line Biofuels & Derivatives, Clariant

Dr. Markus Rarbach, born 1968, is Head of Clariant’s Business Line Biofuels & Derivatives in Munich/Germany. Leading the bioethanol operations, Dr. Rarbach is, among other tasks, responsible for the development and commercialization of Clariant’s sunliquid® technology for the conversion of cellulosic feedstock into 2nd generation bioethanol and other biobased chemicals. Dr. Markus Rarbach studied Biotechnology at the Technical University of Berlin. He worked as a PhD student at the Institute of Biotechnology at the Technical University Berlin where he obtained his doctorate as “Dr.-Ing.” in 1999. As a Postdoc Dr. Rarbach worked at the Institute of Biochemical Kinetics at the Max-Planck-Institute for Biophysical Chemistry in Göttingen with Nobel laureate Dr. Manfred Eigen. In November 2000 he joined DIREVO Biotech AG as Department Head of Screening and Automation and assumed the responsibilities of Vice President Operations at DIREVO in 2005. In November 2006 Dr. Rarbach joined Süd-Chemie as Head of Biocatalysis at its Corporate Research & Development Department in Munich. Following the acquisition of Süd-Chemie by Clariant in 2011, he took on the role of Head of Start-up Business Project Biofuels & Derivatives at Clariant’s Group Biotechnology. As of January 2018, Dr. Rarbach is leading the Business Line Biofuels & Derivatives to further the focus on the commercialization of bio-ethanol, licenses and enzymes.


Panels:

The project receives funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No 820482.